Thu Apr 26, 2012 12:22 am
Probuphine Well Tolerated in Late-Stage Trial
Fri, 02/10/2012 - 5:43am
Get today's drug discovery & development headlines and news - Sign up now!
Titan Pharmaceuticals Inc. announced the results of an open-label, six-month safety re-treatment study (PRO-811) of patients with opioid dependence who previously completed a full six months of treatment in Titanâ€™s confirmatory Phase 3 clinical trial of the investigational drug Probuphine. In the 85 patients enrolled in this retreatment study, Probuphine was shown to be well tolerated, including the implant insertion and removal procedures, with a low incidence of adverse events and overall safety profile similar to that observed in the confirmatory Phase 3 study. Patients also reported a decreased use of illicit opioids, good control of opioid withdrawal and cravings and high overall satisfaction with Probuphine. These data build upon the positive results of the Probuphine Phase 3 program reported to date and further support the companyâ€™s preparation of a New Drug Application (NDA) for Probuphine.
Titan also provided an update on the preparation of the NDA for Probuphine, which it now plans to submit in the third quarter of this year. The company is on track to complete its analytical testing of Probuphine to provide additional Chemistry, Manufacturing and Control (CMC) data requested by the U.S. Food and Drug Administration (FDA) along with its preparation of the integrated clinical data, summary reports and electronic document preparation by mid-year. The manufacturing facility expansion and qualification for commercial scale production of Probuphine is in process, but has been slightly delayed due to longer than expected lead-time on air handling equipment and the manufacturing of three qualification batches is now expected to be completed in September.
â€œAs a clinician, I know first-hand how desperate the patient need is for a safe and effective treatment for opioid dependence, especially one that patients feel improves their condition and their compliance,â€ said Walter Ling, M.D., Professor of Psychiatry and Director, Integrated Substance Abuse Programs at the David Geffen School of Medicine at UCLA. â€œThese data continue to show that Probuphine could represent a new and potentially improved method of delivering buprenorphine to patients - one that improves the quality of life of patients, lessens physiciansâ€™ concerns about compliance and medication diversion and shifts the treatment landscape.â€
The safety re-treatment study enrolled 85 patients at 18 sites and provided six months of open-label treatment with Probuphine. The study protocol included standard safety monitoring of patients similar to the previous clinical studies, including periodic evaluation of opioid withdrawal and craving symptoms and self report of illicit drug use. Additionally, the study included a patient satisfaction survey that was completed by 53 of the 67 patients who finished the study. Highlights of the findings include:
â€¢ Overall, more than 80% of eligible patients from the confirmatory Phase 3 clinical trial consented for treatment in this follow-on safety study; of these, 86% of the patients who had been treated with Probuphine in the Phase 3 trial consented for re-treatment (patients in the Phase 3 trial received Probuphine, placebo or sublingual buprenorphine)
â€¢ 67 patients (79%) completed the six-month retreatment study, with more than 90% of the completers indicating that, if given the option, they would elect to receive further treatment with Probuphine
â€¢ At the end of treatment, 80% of patients reported that they had not used illicit opioids within the last two weeks
â€¢ According to patient-reported data, as well as clinician assessments, symptoms of opioid withdrawal were well-controlled during the study
â€¢ Patients self-reported that opioid cravings were also well-controlled throughout the study
â€¢ Nearly 95% of patients reported that they were able to improve their lives while taking part in the study
â€¢ More than 90% of the patients that were randomized to sublingual buprenorphine in the previous Phase 3 trial reported that Probuphine made it easier to comply with taking their medication
â€¢ 17 of the 85 patients used supplemental rescue medication with a mean of 10 days and median of seven days of use out of the possible 168 days of the study
â€¢ Approximately 11% of treated patients received a dose increase to a total of five Probuphine implants during the study
â€¢ Probuphine was well-tolerated, including the implant insertion and removal procedures; the most common adverse events reported were headache (12%), upper respiratory infection (8%), back pain (6%) and urinary tract infection (6%)
The full data from this safety re-treatment study will be submitted for future publication.
â€œWe are extremely pleased with these additional safety results as they continue to support the potential of Probuphine as a new and innovative treatment option for patients suffering from opioid dependence,â€ said Katherine L. Beebe, Ph.D., Principal Investigator for the study and Executive Vice President and Chief Development Officer of Titan. â€œThese results complete the planned clinical development program and are an important addition to the database necessary to establish potential safety and efficacy of Probuphine, and fully support our ongoing discussions with potential partners for the future commercialization of Probuphine.â€
Date: February 9, 2012
Source: Titan Pharmaceuticals Inc.
Thu Apr 26, 2012 4:50 am
Thu Apr 26, 2012 9:12 am
Thu Apr 26, 2012 10:55 am
Thu Apr 26, 2012 11:37 pm
Fri Apr 27, 2012 4:52 am